Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lantern Pharma ( (LTRN) ) has provided an update.
On September 19, 2025, Lantern Pharma Inc. held its Annual Meeting of Stockholders where six directors were elected, a one-time repricing of certain stock options was approved, and the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are expected to impact the company’s governance and financial management, potentially influencing its strategic direction and operational efficiency.
The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Lantern Pharma Inc. operates in the biotechnology industry, focusing on developing precision oncology therapies. The company leverages artificial intelligence and machine learning to advance its drug discovery and development processes, aiming to improve outcomes for cancer patients.
Average Trading Volume: 261,741
Technical Sentiment Signal: Sell
Current Market Cap: $44.93M
For detailed information about LTRN stock, go to TipRanks’ Stock Analysis page.